Remedy Entmt Oyj (RMDEF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, dear Remedy investors, welcome to the webcast for Remedy's full year results of 2025. My name is Aapo Kilpinen from Remedy's Investor Relations. Joining with me today are Remedy's interim CEO, Markus Päki, and Remedy's CFO, Santtu Kallionpää. Markus will guide us through the quarter and the full year, and then Santtu will dive deeper into the financials. We'll then look at the outlook for 2026 before moving to the Q&A session at the end of the webcast. If you have any questions, feel free to leave those already at the text box below the webcast. But without further ado, Markus, please, how did the quarter go? Well, welcome everybody on my behalf as well. It's an end of an interesting year for Remedy, so let's look back at what happened. So starting with Q4, financial highlights, our revenue was 17 million. Large growth, it was almost on the record level for us, but not quite record quarter, but very close to that. EBITDA, 3.9 million, and EBIT was 0.0 million positive. Cash flow was a bit negative for the comparison period. One of the major events that happened during Q4, we of course had the change of the CEO and the chairman of the board. So I took the role of the interim CEO and Henri Österlund took the role of chairman of the board. We decided on a new option plan for our staff for 2025. And we also had a repurchase program for 50,000 of our own shares to optimize our capital structure a bit. And of course, the huge news was that we unveiled Control Resonant to be published in 2026. Looking at the full year numbers, revenue was 59.5 million, 17% growth from 24, EBITDA at 11.3 million, and EBIT was then almost 15 million negative, which is the same amount as the last quarter announced firebreak impairment that we did. Cash flow was positive f...